Hengrui Medicine: Subsidiary product Perfluorohexane eye drops approved for marketing.

Hengrui Pharmaceutical announced on the evening of July 3 that its subsidiary Chengdu Shengdi Pharmaceutical recently received a notice from the National Medical Products Administration approving the listing of the company's perfluorohexyl octane eye drops for the treatment of dry eye related to meibomian gland dysfunction. In addition, the company's subsidiary, Suzhou Shengdi Yiabiological Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration to conduct clinical trials of SHR-4506 injection. SHR-4506 injection is a class 1 therapeutic biological product independently developed by the company, intended for the treatment of advanced malignant tumors.